23^rd International Conference on
Cancer Research & Pharmacology

Radionuclide therapy in patients suffering from bone metastases is used since decades. Primarily this treatment was approved for

bone pain palliation (89Strontium in bone lesions due to HRPC, 153Samarium for osteoblastic bone metastases, independently

from the primary tumor). In 2013, 223Radium was approved for treatment of HRPC bone metastases. A prolongation of median

survival in the verum group vs. placebo group of 3.6 months was observed. β-emitting radionuclides in combination with chemotherapy

may lead to a significant prolongation of median survival up to 10 months compared to patients only getting radionuclides, together

with also significant improvement of pain syndrome. More recently radiolabeled PSMA ligands are used in clinical trials and on a

compassionate use basis for diagnostic procedures in various primary, mainly prostate cancer tumors as well as in therapy of those

tumors expressing PSMA on the cell surface and showing sufficient tracer uptake. Studies with either 68Gallium-PSMA PET/CT

or 99mTc-PSMA for diagnostic procedures and 177Lutetium-PSMA ligands for treatment of HRPC bone and soft tissue lesions

are showing high sensitivity and for treatment excellent response rates given their predominant use as last line treatment. However,

prospective studies are needed to define the role of this approach in the management of advanced prostate carcinoma.